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Resumo 
O melanoma é um cancro agressivo que pode facilmente ser confundido com nevos benignos quando 
nas fases iniciais de desenvolvimento. Com um diagnóstico precoce, a lesão pode ser removida 
cirurgicamente, mas esta camuflagem dificulta esse diagnóstico. Por isso, soluções terapêuticas para 
tratar melanoma em fases mais avançadas são cruciais para atingir boa qualidade de vida e taxa de 
sobrevivência do paciente. A terapia standard para tratar melanoma em estadios mais avançados envolve 
quimioterapia com Dacarbazina, um agente aprovado pela FDA em 1975, mas baixa resposta ao 
tratamento e taxa de sobrevivência encorajam a investigação de outras opções de tratamento. 
Alternativas quimioterapêuticas, como um análogo oral da Dacarbazina, ou fármacos metálicos como a 
cisplatina existem, mas sem se destacarem do tratamento padrão, Dacarbazina. A combinação de agentes 
quimioterapêuticos pode ajudar na resposta ao tratamento, levando, contudo, a mais efeitos secundários 
sem melhorar a taxa de sobrevivência. Agentes imunoterapêuticos, que induzem ou fortalecem a 
resposta imunitária contra células tumorais, como Ipilimumab, Interferão-Alfa, Interleucina-2 e 
Timosina Alfa 1 obtiveram melhores resultados em termos de resposta e sobrevivência, sendo que 
Ipilimumab foi aprovado como um tratamento de primeira linha na Europa. Ainda assim, necessitam de 
monitorização de efeitos secundários para garantir qualidade de vida dos pacientes, o Interferão-Alfa e 
Interleucina-2 são especialmente tóxicos. Outra alternativa ainda, apelidada de terapia dirigida, ataca os 
caminhos de sinalização usados pelas células tumorais para crescerem e se replicarem, tendo já alguns 
tratamentos aprovados com um desempenho superior à Dacarbazina, como Dabrafenib e Cobimetinib. 
A limitação destes tratamentos reside na resistência ao fármaco que é desenvolvida ao longo do 
tratamento, impedindo um tratamento extenso com o mesmo agente terapêutico. Finalmente, é possível 
ainda combinar agentes com ações diferentes, correndo sempre o risco de aumentar a severidade ou 
quantidade de efeitos secundários sobre o paciente. 
Qualquer opção terapêutica usada resulta invariavelmente em efeitos secundários, que podem ser 
minimizados através da construção de um sistema de entrega adequado. Sistemas de entrega de fármacos 
almejam: aumentar a aceitação de fármaco, ao aumentar a quantidade de fármaco disponível no local 
alvo e minimizar efeitos secundários, ao reduzir a exposição de células e tecidos saudáveis aos agentes 
terapêuticos. Conseguir esta administração focada em células doentes pode ser conseguida de várias 
formas, desde exploração das características físico-químicas das células ou tecido alvo, ou usando 
estímulos externos para guiar o sistema ou induzir a libertação do fármaco. 
Em trabalho prévio, Cuphen, um composto de cobre e fenantrolina com efeitos de oxidação do ADN e 
inibição de aquaporinas, foi incorporado em lipossomas. Tanto o Cuphen livre como os liposomas com 
Cuphen exibiram baixa atividade hemolítica e nenhuma toxicidade in-vivo, mantendo ao mesmo tempo 
alta citotoxicidade contra linhas celulares de melanoma e cancro do cólon. Recentemente, outras 
formulações com Cuphen foram testadas num modelo singénico murino de melanoma, exibindo 
sensibilidade ao pH e debilitando seriamente o crescimento tumoral. Como as formulações prévias, estes 
lipossomas com Cuphen também exibiram baixa atividade hemolítica e nenhuma toxicidade in-vivo. As 
formulações desenvolvidas no trabalho mencionado baseavam-se em direcionamento passivo do sistema, 
explorando o efeito de Permeação e Retenção Aumentadas para facilitar a acumulação dos lipossomas, 
e usando o característico baixo pH do ambiente tumoral para libertar o fármaco. 
O apelo dos lipossomas como sistemas de entrega de fármacos advém da sua flexibilidade: vesículas 
lipídicas, constituídas por uma ou mais bicamadas lipídicas separadas por meios aquosos, torna estes 
sistemas compatíveis tanto para a incorporação de compostos hidrofílicos como hidrofóbicos. Além 
disso, a própria composição lipídica das vesículas pode ser feita à medida da utilização, sendo possível, 
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por exemplo, alterar a rigidez, sensibilidade ao pH e tempo de circulação destes sistemas O processo de 
produção dos lipossomas pode também ser ajustado para obter lipossomas de um determinado diâmetro, 
aumentando ainda mais a flexibilidade deste sistema.  
Neste projeto, nanopartículas de óxido de ferro foram incorporadas em lipossomas sensíveis ao pH com 
Cuphen, para adicionar direcionamento físico à formulação. A produção dos lipossomas foi feita pelo 
método de desidratação e rehidratação, com uma composição lipídica baseada no trabalho prévio do 
grupo de investigação, que como mencionado obteve um sistema de entrega de Cuphen funcional no 
modelo animal, sem toxicidade. O direcionamento magnético serviria para aumentar a retenção dos 
lipossomas de longa circulação nos locais tumorais, e consequentemente melhorar a resposta ao 
tratamento ao disponibilizar mais Cuphen, mais rapidamente, às células-alvo. A utilização de 
magnetossomas em aplicações médicas tem visto alguma investigação: sistemas de imagem e terapia, 
chamados de teranósticos, podem explorar a versatilidade dos lipossomas e a sensibilidade das 
nanopartículas de óxido de ferro a campos magnéticos, sendo que as partículas tanto são um bom 
contraste de Ressonância Magnética como podem ser usadas para despoletar a libertação do fármaco. 
Para produzir as nanopartículas de óxido de ferro, foi necessário encontrar um método documentado 
que produzisse nanopartículas biocompatíveis e solúveis em água de forma simples e rápida, visionando 
uma facilitação de uma possível ampliação da produção. Um método fácil, de um passo, assistido por 
microondas foi usado para produzir nanopartículas de óxido de ferro revestidas com Dextrano, 
conseguido ao modificar um processo documentado com um revestimento que, segundo a literatura, 
permitiria produzir partículas com características semelhantes às do processo original, mas reduzindo a 
quantidade de passos necessários na produção. O revestimento das nanopartículas serve tanto para 
aumentar a biocompatibilidade das mesmas como para reduzir a agregação. As nanopartículas assim 
produzidas eliciaram uma resposta hemolítica inferior a 4% e não interferiram com a atividade citotóxica 
do Cuphen. A citotoxicidade das nanopartículas de óxido de ferro, Cuphen e combinação de 
nanopartículas com Cuphen foram avaliadas pelo teste colorimétrico MTT, onde um composto amarelo 
é metabolizado pelas células viáveis em cultura para um composto púrpura, quantificável por 
espectrofotometria. 
A validação do método de produção de magnetossomas foi conseguida através de um teste de 
centrifugação, onde lipossomas com Cuphen e magnetosomas com Cuphen foram expostos a um ciclo 
curto de centrifugação numa centrífuga de bancada. Segundo o trabalho previamente executado pelo 
grupo de investigação, os lipossomas com Cuphen com um diâmetro inferior a 200 nm não precipitam 
quando submetidos a um ciclo de centrifugação de 15,000 × g durante 30 minutos. necessitando no 
mínimo da aplicação de 250,000 × g durante 120 minutos. Os lipossomas com Cuphen não precipitaram, 
enquanto os magnetosomas com Cuphen formaram um precipitado, com 59 e 80% do lípido total para 
magnetossomas de 170 e 270 nm, respetivamente., Foi também verificada uma redução da eficiência de 
incorporação do Cuphen nos magnetossomas: 59 e 66% para magnetossomas de 170 e 270 nm, 
respetivamente, comparativamente ao valor obtido para lipossomas de Cuphen (100 e 88% para 170 e 
270 nm, respetivamente) A quantificação do teor de lípido e Cuphen nas formulações desenvolvidas foi 
baseada em métodos colorimétricos.  
Os magnetossomas também foram testados em termos de atividade hemolítica, exibindo atividade 
abaixo dos 5%, sendo por isso considerados seguros para administração intravenosa. Para validar as 
propriedades magnéticas dos magnetossomas, foi desenhado um teste in vitro de magnetismo, onde um 
volume da suspensão dos magnetossomas foi colocado numa placa e exposto ao campo de um íman 
permanente de Neodímio-Ferro-Boro durante tempos diferentes.  A concentração de lípido e Cuphen 
iniciais bem como nas zonas sobre o íman e opostas ao íman foram quantificadas. De facto, os 
magnetossomas exibiram qualidades magnéticas: a exposição a um campo permanente resultou num 
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aumento de 31% da concentração de Cuphen por cima da zona do íman, ao fim de 19 horas. Contudo, 
não se observaram variações em termos de concentração de lípido sobre as mesmas áreas em estudo. 
Para além disso, quando o teste foi repetido com Cuphen na forma livre e partículas de óxido de ferro 
não incorporadas, não se obtiveram os mesmos resultados que com os magnetossomas.  
No futuro, métodos de quantificação de ferro podem ser utilizados para conseguir avaliar diretamente a 
eficiência de incorporação das nanopartículas, o método de produção das nanopartículas de óxido de 
ferro pode ser ajustado para produzir partículas mais pequenas de forma consistente, e testes in-vivo 
podem ser conduzidos num modelo animal para confirmar se o direcionamento extra providenciado 
pelas nanopartículas se traduz num aumento da resposta ao tratamento. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-Chave: melanoma, partículas de óxido de ferro, lipossomas sensíveis ao pH, sistemas de 
entrega de fármacos, direcionamento magnético  
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Abstract 
Melanoma is an aggressive cancer that can easily be mistaken with normal skin features, like moles, 
when in early stages. This complicates early diagnosis, so effective therapeutic solutions for melanoma 
in more advanced stages is vital for patient quality of life and survivability. If surgery is not applicable, 
the standard option for advanced stage melanoma is chemotherapy with dacarbazine, but low positive 
response and overall survival rates encourage research into other treatment options. 
Any therapeutic option used will inevitably result in adverse side effects, which can be minimized by 
using a drug delivery system. Drug delivery systems aim to both increase drug uptake, by enhancing 
drug availability at target sites, and minimizing adverse side effects, by reducing healthy cell exposure 
to the therapeutic agents. This targeting of unhealthy cells can be achieved in different ways, from 
exploiting the physiochemical characteristics of the target cells or tissue, to utilizing external stimuli to 
guide the drug delivery system or induce drug release. 
In this work, iron oxide nanoparticles were prepared and incorporated into Cuphen pH-sensitive 
liposomes for a further targeting delivery using external stimuli. Cuphen is a copper-phenanthroline 
compound with both DNA oxidising and aquaporin inhibition effects and it has been shown promising 
results in melanoma cell lines using liposomal formulations. Now, a one-step microwave assisted 
method was used to produce Dextran coated iron oxide nanoparticles, which elicited a low haemolytic 
response and did not interfere with Cuphen’s cytotoxic activity. The resulting magnetosomes were 
guided to a target area via a magnetic field: exposure to a permanent magnetic field resulted in an 
increase of Cuphen concentration over the magnet area. However, there was not a significant increase 
in lipid concentration over the magnet area when compared to free Cuphen. Further studies must be 
performed.  
As future strategies, iron quantification methods can be employed to directly quantify the iron oxide 
nanoparticles’ incorporation efficiency and the iron oxide nanoparticle production method can be 
adapted to consistently make smaller particles, and, finally, in-vivo tests can be conducted in an animal 
model to confirm whether the added targeting capabilities translate into an increase in treatment response. 
 
 
 
 
 
 
 
 
 
 
Keywords: melanoma, iron oxide nanoparticles, pH-sensitive liposomes, drug delivery systems, 
magnetic targeting  
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Abbreviations 
Abbreviation Description 
  
CHEMS cholesteryl hemisuccinate 
Cuphen Cu2+(1,10-phenanthroline)3 
EPR Enhanced Permeability and Retention 
Dex-70 Dextran - 70 
DLS Dynamic Light Scattering 
DMPC Dimiristoyl phosphatidyl choline 
DMSO 
DNA 
Dimethyl sulfoxide 
Deoxyribonucleic Acid 
DOPE Dioleoyl phosphatidyl ethanolamanine 
DSPE-PEG(2000) Distearoyl phosphatidyl ethanolamine covalently 
linked to to polyethylene glycol (2000) 
HEPES Hydroxyethyl piperazineethanesulfonic acid 
IC50 Half maximal inhibitory concentration 
ICP-MS Inductively coupled plasma mass spectrometry 
I.E. Incorporation Efficiency 
IL-2 Interleukin-2 
IFN Interferon 
IONPs Iron Oxide Nanoparticles 
kcts Kilo counts 
MTT Dimethylthiazolyl diphenyltetrazolium bromide 
MRI Magnetic Resonance Imaging 
MW Molecular Weight 
MWCO Molecular Weight Cut-Off 
NdIB Neodymium – Iron – Boron 
PBS Phosphate-buffered saline 
PE Phosphatidylethanolamine 
PEG Polyethylene glycol 
PdI Polydispersity Index 
SPIONS Superparamagnetic Iron Oxide Nanoparticles 
TEM Transmission Electron Microscopy 
UV Ultraviolet 
UV/Vis Ultraviolet/Visible 
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1. Introduction 
1.1. Motivation 
Melanoma is a common, aggressive cancer derived from the malignant transformation of melanocytes, 
normally tied to UV exposure that typically starts in the largest human organ, the skin, though it can 
very rarely manifest itself in the eye or mucous membranes. In its cutaneous form, it assumes the 
likeness of moles and other skin features [1], camouflaging it until a larger, more obvious lesion is 
formed, or until a trained eye recognizes it. If the patient or the physician suspect of a mole or other skin 
feature, a biopsy might be conducted, to confirm the nature of the tissue.  
 
Figure 1.1: Superficial Spreading Melanoma lesions. Irregular edges are a key telling sign of a possible cancerous lesion.  
Upon finding a thick (1 to 4 mm) tumour, a sentinel lymph node biopsy follows, to evaluate whether the 
cancer has already metastasized. To find the sentinel lymph node, one must use blue dye and a 
radioactive tracer, following it to the first lymph node it reaches, removing it immediately and sending 
it to analysis. This works because lymph nodes have valves that stop backflow, making lymph flow in 
one way only. This means there will always be a node closest to the tumour, being the node responsible 
for draining it, and therefore susceptible to capture its cells. For an invasive, metastatic manifestation, 
surgery stops being the main therapy, and alternatives like chemo-, immuno- and targeted therapy come 
into play.  
 
Chemotherapy allows for a systemic reach over the cancerous sites and cancerous cells in circulation, 
though it tends to affect healthy tissues as well, leading to side effects. Furthermore, chemotherapy for 
cancer treatment has a fairly narrow range for dose safety and effectiveness, meaning that the window 
Figure 1.2: Lymph node anatomy and sentinel lymph node biopsy 
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between an ineffective treatment and a life-threatening one is small [2]. Reducing the side effects and 
the administered dose while still achieving an effective treatment can come via targeting. Targeting can 
be achieved in different ways [3]: 
• Direct: literal, via the usage of injections, lotions or other topical applications; 
• Passive: exploiting pre-existing characteristics of the diseased tissue, like vasculature and 
lymphatic drainage defects; 
• Physical: using physical phenomena like magnetic fields, ultrasound, pH to guide and/or release 
the drug; 
• Active: based on specificity towards certain overexpressed ligands in the target tissue or cell. 
There are challenges in such an approach, since new formulations must be tailored to the specific 
characteristics of the target tissue and, given that we still don’t know much about the pharmacokinetics, 
biodistribution and toxicity of most targeting systems, they must be evaluated as separate entities, 
studied one by one until the theoretical body of knowledge catches up. This means that, even when a 
known drug is used, both the carrier and drug-carrier combination need profiling to assure that in 
optimizing drug intake we’re not compromising other tissues down the line, as the novel treatment is 
metabolised and excreted. For instance, one must consider [4]: 
• Carrier capacity and drug potency: in order to avoid toxicity due to excessive carrier 
administration, drug incorporation must be as high as possible; 
• Drug – carrier compatibility: the drug must be able to preserve their physicochemical 
properties during their incorporation to the selected carrier, and remain associated with the 
carrier long enough to reach the target tissues; 
• Carrier biocompatibility: the carrier should be metabolized and/or excreted effectively 
enough that any possible side effects of its administration are reduced when compared to the 
free drug. 
• Drug release rate: the drug must be able to dissociate from the carrier in such a way that a 
therapeutic concentration of it is maintained in the target tissues, since a slow release might 
result in lower effectiveness, and a rapid release might not be an improvement over the free 
drug. 
Liposomes as drug carriers are versatile and have been extensively studied, being able to passively target 
the incorporated material when administered parenterally [5]. To fulfil this, one must increase their 
circulation time in order to, via defective endothelium and insufficient lymphatic drainage of tumours, 
they can accumulate in the tissue and, relying on normal cell digestion or pH activation to break these 
carriers apart, release their contents. 
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1.2 Objectives 
The present work had two major goals: 
• Production of water soluble, biocompatible, superparamagnetic Iron Oxide Nanoparticles 
(IONPs), in a one-pot and one-step fashion; 
• Incorporation of these nanoparticles in a delivery system loaded with a cytotoxic compound 
enhancing the targeting to solid tumours by applying a magnetic field over the target. 
To pursue these goals, a set of sub-objectives were set: 
• Review existing processes of IONP production, and choose a base procedure that is known to 
produce water soluble, biocompatible, superparamagnetic particles; 
• Attempt to modify this base procedure, making it as quick and facile as possible; 
• Verify that the modified procedure still produces IONPs with the desired size and 
biocompatibilty; 
• Choose a delivery system to incorporate the IONPs; 
• Choose a compound with cytotoxic potential towards melanoma cell lines; 
• Test whether the IONPs interfere with the elected cytotoxic compound on melanoma cells 
viability; 
• Design nanoparticulate structures that can carry both IONPs and the selected cytotoxic 
compound; 
• Observe whether the new nanoparticulate structure can be magnetically guided. 
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2. State of the Art  
2.1 Melanoma Treatment 
Surgery is the mainstay option for early stage melanoma [6], though the procedural details vary 
depending on its features: the larger the tumour (according to Breslow’s thickness measurement), the 
bigger the safety margin on the excision must be [7]. Melanoma stages range from 0 to 4 and are 
attributed depending on the TNM classification. T stands for tumour, N for lymph nodes and M for 
metastasis. A brief description of the stages is as follows[8]: 
• Stage 0 classifies a small tumour in situ, with no lymph node involvement and no metastasis; 
• Stage 1 (or I) classifies a small tumour that has gone beyond the epidermis, up to 0.8mm thick 
with ulceration or 2 mm with no ulceration, no lymph node involvement and no metastasis; 
• Stage 2 (or II) classifies any tumour larger than those in Stage 1 with no lymph node 
involvement and no metastasis, or a non-metastatic tumour present only in a single lymph node, 
with no primary tumour present;  
• Stage 3 (or III) classifies large tumours that affect multiple lymph nodes, regardless of the 
presence of a primary tumour; 
• Stage 4 (or IV) classifies any tumour that has metastasized. 
When the cancer metastasizes, the prognosis is poor, and survival rates are low [9], [10], mostly because 
of melanoma cells’ resistance to treatment. As such, several treatment options exist, from chemotherapy, 
to immunotherapy and targeted therapy [11] (Figure 2.1). Even with all these options, some of them 
showing an increase in response (reduction of tumours) comparatively to older treatment regimens, there 
is still a severe lack of options that allow for survival benefits [12][13]. 
Figure 2.1: Common melanoma therapies and their main mechanisms 
2.1.1.  Chemotherapy 
Therapy with a cytotoxic agent is the standard treatment for metastatic cancer, having its mainstay drug, 
Dacarbazine, been approved by the FDA in 1975. Even though it has been the custom treatment for 
metastatic melanoma ever since, its response ratio and overall survival benefits are still underwhelming 
(about 15% positive response after 6 months, OS <2% after 6 years) [14][15].  
Another drug, Temozolomide, an analogue of Dacarbazine for oral administration, has shown similar 
performance in overall patient survival [16]. Other agents, like antimicrotubular agents, that disrupt 
Common melanoma 
therapies:
Chemotherapy
Cytotoxic
Antimicrotubular
Platinum analogues
Immunotherapy
T-Cell activation
Cell cycle arrest
Increased tumour 
antigen expression
Targeted 
Therapy
BRAF targeting
MEK targeting
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either microtubular assembly or disassembly, and platinum analogues like cisplatin, that bind covalently 
to DNA and can also work as radiosensitizers also exist. However, they show reduced response rates in 
Phase II trials, or when there’s a higher response rate, it’s short lived [17][18]. Combining different 
cytotoxic agents also didn’t prove more useful in increasing overall survival, and furthermore burdened 
the patients with added toxic side effects [13]. 
2.1.1.1. Potential Chemotherapeutic Agent: Cuphen 
 The therapeutic agent used in this work is Cuphen, a 𝐶𝑢2+-
phenantroline compound that has both a DNA oxidizing action 
as well as an aquaporin inhibition effect [19]. Aquaporins are 
a surface protein estimated to facilitate tumour growth due to 
their key function as water and small solute transporters, 
helping them maintain osmotic pressure. In tumours, where 
they’re overexpressed, they can also facilitate infiltration, cell 
migration and angiogenesis [19][20][21]. Nave et al 
incorporated Cuphen in liposomes and observed a 
preservation of in vitro cytotoxic effects against murine 
melanoma and colon cancer cell lines (B16F10 and C26, 
respectively), as well as human cell lines: epidermal 
carcinoma (A431) and melanotic neuralectodermal tumour 
(MNT-1). Moreoverthe absence of in vivo toxicity when administered parenterally, demonstrated  this 
liposomal formulation as a potential chemotherapeutic option for cancer treatment [19]. 
Recently, Jacinta and colleagues have tested Cuphen nanoformulations in a murine melanoma model. 
One nanoformulation using the same lipid composition as the one selected in this study, attained an 87% 
incorporation efficiency of Cuphen into the liposomes. That formulation exhibited pH sensitivity and 
significantly stunted tumour growth in a syngeneic murine melanoma model [22]. 
2.1.2. Immunotherapy 
Agents that bolster immune response against tumours are immunotherapeutic. Cancer cells are able to 
avoid both cellular death and targeting by immune cells, such as T cells [7]. However, melanoma seems 
to be a very immunogenic cancer [23], and tumour infiltrating lymphocytes, that help the immune 
system in recognizing and responding against cancer, have been proved to cause a positive response in 
people with malignant melanomas [24]. Therapy with Ipilimumab, Interferon-Alpha, Interleukin-2 and 
Thymosin Alpha 1 are the most common [25].  
Ipilimumab is a monoclonal antibody that blocks CTLA-4 receptors. This T-cell surface protein tells it 
when to become inhibited, and blocking it increases T-cell activation. The treatment saw enough 
improvement in survivability compared to the standard chemotherapy (Dacarbazine) treatment to be 
approved as a first line treatment in Europe in 2013 [26].  
Interferons (IFN’s) are cytokines, signalling molecules meant to trigger an immune response against 
viruses, tumours and microbes. They get their name because they interfere with virus replication, acting 
as a vaccine against viral infection. Their antitumoral activity derives from the IFN’s ability to arrest the 
cell cycle, besides increasing T-cell activity and differentiation [27]. Unfortunately, this treatment comes 
with severe toxicity, and though it has shown good performance when compared to standard 
chemotherapy, extensive side effect management is required to maintain some quality of life for the 
patient [28]. 
Figure 2.2: Structure of the organic-inorganic 
compound CuphenCl2 
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Interleukin-2 (IL-2) is another cytokine with antitumoral effects [29], approved by the FDA for 
treatment of metastatic melanomas in 1998 [7]. Besides being a T-cell differentiator and growth factor, 
it also bolsters T and NK-Cells’ cytolytic activity, thus achieving its antitumoral activity [30]. Full 
remission is possible on a very small subset of patients (70% of the full responders, considering only 5-
10% of treated patients fully respond to treatment [31]), though biomarker activity assays need to be 
conducted to avoid serious side effects, like vascular leak syndrome [32]. Vascular leak syndrome 
describes an increase in vascular permeability, resulting in widespread oedema and organ failure, 
occurring in patients treated with either IL-2 or IFN-α [33].  
Thymosin Alpha 1 is a peptide that achieves its antitumoral activity via an increase of tumour antigen 
expression, T-cell differentiation, and increase of cytokine production, such as Interferons and 
Interleukins [34][35]. In a 2010 Phase II study, its effectiveness when combined with IFN-α and 
Dacarbazine was tested, showing a threefold increase in treatment response, but a limited survival 
benefit [36].  
2.1.3. Targeted Therapy 
Targeted therapy in melanoma bases itself on affecting mutated proteins characteristic of metastatic 
disease [37], mainly the BRAF, which mutated version is present in 50% of all melanomas [38] and is 
a part of a signalling pathway responsible for increased growth and proliferation of cancer cells [39]. 
Figure 2.3 shows how the signalling cascade can be triggered through various stimuli. Take special note 
of the left side of the representation, where the BRAF branch of the cascade is depicted: though BRAF 
is the most common mutation, if resistance to the inhibitor is shown, one could target and inhibit MEK 
1/2, to accomplish the same downstream effect [40]. 
BRAF inhibitors can induce rapid recession of metastatic melanoma [41], and several drugs have been 
developed, with different levels of specificity towards the mutated BRAF compared to wild-type BRAF: 
Sorafenib, Vemurafenib and Dabrafenib [7][11].  
Sorafenib, unfortunately, hasn’t shown any therapeutic promise as of late, either as a monotherapy or 
combination therapy, albeit being the first one being studied [42].  
Vemurafenib is 30 times more sensitive to mutated BRAF than to wild-type BRAF [42], and showed 
promise in clinical trials from Phase I, all the way to Phase III, accruing higher overall survival rates in 
Phase III than standard chemotherapy (Dacarbazine) [43][44].  
Dabrafenib has a 100-fold sensitivity to mutated BRAF [42], approved by the FDA in 2013 and with 
similar targeting mechanisms and pharmacodynamics to Vemurafenib [45], and with similar results to 
Vemurafenib in a Phase III trial [46], outperforming standard chemotherapy in progression free survival, 
though an accurate overall survival was not provided due to a reduced follow-up period in this trial. 
However, BRAF inhibitors are limited by development of resistance, besides a certain inconsistency in 
interpatient response. Furthermore, inhibiting this pathway also interferes with healthy cell function, 
even though ever more mutated BRAF specific inhibitors have been developed [41]. 
MEK targeting drugs, like aforementioned, are a way to skirt around the BRAF inhibitor resistance that 
will inevitably develop, since BRAF mutated cells show increased sensitivity and selectivity towards 
MEK inhibitors [47], even though MEK 1/2 mutations are rarer [38].The first approved MEK inhibitor 
drug is Trametinib, an oral MEK 1/2 inhibitor, approved by the FDA in 2013 as a monotherapy [48]. 
Reviewing Figure 2.3 we can see that inhibiting MEK 1 or MEK 2 will also result in stunted growth, 
development and proliferation of cancer cells, and it results in improved progression free survival and 
overall survival when compared to standard chemotherapy [40].  
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Cobimetinib was approved in 2015, and is also a highly specific MEK inhibitor, taken orally in 
conjunction with Vemurafenib [49]. In a Phase III trial, the combination has shown improvement in 
response rates and progression free survival compared to both placebo and Vemurafenib monotherapy 
[50]. 
Nevertheless, MEK inhibition faces the same problem as BRAF, in that resistance to inhibition will 
inevitably arise [48], and that BRAF inhibitor resistance acquired via exposure to treatment can also 
reduce response to MEK inhibitors [51]. 
 
Figure 2.3: MAPK signalling pathway, extracted from [52] (24/10/2018) 
2.1.4. Combination therapy 
In an attempt to improve response and survival against a cancer with unpredictable resistances and an 
aggressive nature, various combination therapies have been tested, and combining therapies has become 
commonplace in managing this disease [11][38][41][53]. They exploit the complementary effects of 
chemo-, immuno- and targeted therapy. The aforementioned BRAK MEK inhibitor combination is an 
example of a combination therapy, shown to delay the onset of resistance and attain increased response 
when compared to BRAK inhibitor monotherapy [54]. Dacarbazine plus Ipilimumab was also studied, 
again achieving higher response rates and overall survival than monotherapy [55].  
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A Phase III trial studied the effects of a combined therapy of Cisplatin, Vinblastine, Dacarbazine, 
Interleukin-2 and Interferon versus high dose IFN alpha-2b, combining chemotherapy agents (DNA 
oxidizer, antimicrotubular agent and cytotoxic agent, respectively) with immunotherapy (both are 
cytokines). Good response rates and higher remission free survival were attained, but without any benefit 
to overall survival, and with added toxicity towards the patient when compared to high dose IFN α-2b 
[56]. This illustrates that, even though combining different agents can be inviting, one must consider the 
added toxicity risks set upon the patient. 
2.2. Liposomes in Drug Delivery 
Liposomes are lipid vesicles constituted by one or more concentric phospholipid bilayers enveloping 
aqueous compartments, as seen in Figure 2.4. These systems self-assemble when a dry lipid film is 
hydrated with an aqueous solution [57].  
 
Figure 2.4: Liposome. Illustrated are their carrying capabilities, and some surface functionalization options (Stock Image) 
Due to their structure liposomes are versatile carriers, with the ability to carry both hydrophilic and 
hydrophobic drugs, since they can be inserted on either the aqueous compartment or in the lipid bilayer, 
respectively, [11]. Being highly biocompatible, liposomes constitute one of the most studied and 
efficient drug delivery systems [58]. As previously mentioned, they are capable of transporting both 
hydrophilic and lipophilic drugs [59] and their surface can be modified promoting  long blood circulation 
times, targeting specific ligands, enhancing accumulation at affected sites and consequently reducing 
toxic side effects [60].  
Liposomes can be designed according to the compound  that is meant to be incorporated, the 
physiological conditions of the target, and the desired application (diagnostic or treatment) [61].  
One usage of liposomes is as a passive carrier. The Enhanced Permeability and Retention (EPR) effect 
that occurs in tumour sites can be exploited effectively: most drugs with a low molecular weight are not 
retained in tissues irrigated by vessels with defective endothelium and lymph drainage, however 
liposomes are large enough to accumulate in such areas [62]. This effect happens because when a tumour 
grows big enough (about 2-3 mm), angiogenesis is induced, so it continues receiving adequate levels of 
oxygen and nutrients. These new vessels do not possess the qualities of those in the rest of the body: 
they are irregular in shape, and their defective endothelium means they are leaky [63]. 
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2.2.1. pH Sensitive Liposomes 
pH sensitive liposomes are a type  of liposomes that have been developed to achieve stability and long 
blood circulation times, while also facilitating intracellular delivery of incorporated material [64]. These 
liposomes destabilize in acidic conditions such as those observed around the tumour environment [65]. 
Coating them with polyethylene glycol (PEG) allows longer blood circulation times by stabilizing the 
liposome and reducing the interactions with biological milieu [66]. In addition, the inclusion in the lipid 
composition of pH sensitive constituents  like phosphatidyl ethanolamine (PE) and its derivatives, like 
Dioleoyl phosphatidyl ethanolamine (DOPE) will give liposomes the intended pH sensitivity [64]. 
The liposomes used in the present work included in the lipid composition Cholesteryl hemisuccinate 
(CHEMS). Previous studies demonstrated that the presence of CHEMS was able to destabilize and 
release the incorporated compounds from liposomes at pH below 6.0 [22]. Poly(ethylene glycol) 
covalently linked to distearoyl phosphatidyl ethanolamine (PEG-DSPE) was also used in the lipid 
composition to achieve the aforementioned clearance time delayed [67][68].  
Recently, pH sensitive liposomes have been used to reduce side effects of the incorporated compounds, 
by protecting them from biological milieu and thus reducing haemolytic activity in the case of 
problematic drugs, while maintaining cytotoxic properties [69]. They were also used to develop a 
theranostic systems with high serum stability and tissue uptake [70][71]. 
2.3. Magnetic Particles 
Physical targeting systems that rely on magnetic fields aren’t a novel concept. Their use to guide medical 
devices can be traced as far back as 1950, while magnetic particles as a contrast agent have been studied 
since the 60’s [72]. Typically, the mode of action of a magnetic targeted system is to be injected into 
the blood stream and, by applying a strong magnetic field over the target tissue, the drug can be slowly 
released from the magnetic carrier [73]. These carriers attain their magnetism due to constituents like 
magnetite, maghemite and other iron oxides, nickel, cobalt and neodymium [74].  
Besides their use as a contrast agent in Magnetic Resonance Imaging (MRI), magnetic particles have 
been researched as: 
- Hyperthermia or thermal ablation agent for cancer therapy, where an oscillating magnetic 
field is used to create heat in target areas where the particles are [75]; 
- Controlled drug release systems, where the release timing and target tissue are controlled 
via exposure to an external magnetic stimulus, thus avoiding healthy tissue damage [76]; 
- Tissue engineering, for instance as scaffolding materials, so that magnetic fields can be used 
to mechanically stimulate cells, enhancing tissue formation and remodelling [77]; 
- Theranostics, so called “all in one” systems, that allow for targeting, imaging and treatment 
[78], possibly allowing for a “personalized nanomedicine”, where one could see in real time 
the targeting and effects of treatment, and adjust the treatment accordingly [79]; 
- Lab-on-a-chip, low-cost, efficient microfluidic systems that can be used for diagnosis and 
monitoring [80], one such example being a malaria diagnosis device that uses magnetic 
resonance relaxometry for high sensitivity detection of malaria biomarkers [81]; 
- Drug carriers, that rely on magnetic fields to deliver their drug load to the target tissue [82]. 
The applications of iron oxide nanoparticles in particular have been a study subject for over 50 years 
[83], and several ways of producing them have arisen, ranging from physical, to chemical, to 
microbiological, each one with advantages and disadvantages [84]. The most common method is co-
precipitation, where ferric and ferrous oxides are mixed in very basic solutions (~11 pH), and the pH is 
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manipulated to either facilitate nucleation (the formation of the core), or the growth of the nucleus, with 
more basic solutions facilitating growth and more acid solutions facilitating nucleation. Nonetheless, 
particles produced by this method have considerable size and shape variability, depending on the 
solvents used, the salts that provided the iron ions and their ratios, and other experimental parameters 
[85], as seen in Figure 2.5. 
 
Figure 2.5: TEM imaging of commercially available iron oxide nanoparticles [86]. 
The process used to produce SPIONS in this work does not use co-precipitation, and is based on an 
optimization of the production of Dextran coated SPIONS (similar to the MRI contrast agent Feridex®), 
using microwaves as a heat source [87]. Microwave assisted methods have existed for a couple of 
decades, slowly but surely being adopted as a means to reduce reaction times, starting with the usage of 
adapted kitchen microwaves to the dedicated equipment of today [88], where one can control pressure 
and temperature, besides reaction time, and even control the reaction temperature [89][90]. Dielectric 
heating ends up being more effective than relying on conduction and convection, and microwave 
reactors have allowed for higher yields, quicker and greener reactions (no fuel being burned, no oil bath 
to dispose of) [87].  
 
Figure 2.6: Microwave synthesis reactors similar to the one used in this work. This equipment allows for functions such 
as: long reaction times, temperature setting, performing the reaction at high pressure, stirring of the contents [90]. 
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Furthermore, microwave assisted reactions allow for controlled particle size and shape, unlike co-
precipitation, while sharing in its celerity [85][91]. The main principle behind this production method 
and most wet chemical methods is described neatly in Figure 2.7 [92]: 
 
Figure 2.7: Basic principle of wet chemical production of FeO nanoparticles [92] 
An Iron precursor (like an iron salt, such as the FeCl3 and hydrazine mix that is used by Osborne et al 
[87]) is dissolved in a solvent, be it water or another, and, depending on the production method, a ligand 
is added to stabilize the particles and is usually meant to prevent particle aggregation via Van der Waals 
forces. Then, an external stimulus is added to lead to precursor decomposition, forming the iron cores. 
In one-step methods, one can use the ligand to effectively give the iron cores a coating that could increase 
their biocompatibility [87][93]. 
2.4. Liposome-SPION Delivery Systems 
These mixed systems, also called magnetoliposomes, combine the carrying versatility of liposomes with 
the physical targeting properties of SPIONS. The points concerning liposomes apply to 
magnetoliposomes, since the iron oxide particles might be incorporated in liposomes, as seen in Figure 
2.8: they can be included into the lipid bilayer, in the aqueous compartment, or at liposomal surface [94]. 
 
Figure 2.8: Possible magnetic nanoparticle localisations in liposomes, from [94] (24/10/2018) 
This means that the same procedures performed to extend blood circulation times, avoid 
immunogenicity and increase biocompatibility of liposomal formulations are valid for 
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magnetoliposomes [95]. In this sense, to effectively target the diseased tissues, the geometry of the field 
is crucial for achieving an optimal targeting. SPIONS, like the ones used in the present work, when 
combined with powerful permanent magnets (Neodymium – Iron – Boron), allow a penetration depth 
of 10-15 cm [96]. Magnetic implants have also been studied, and magnetic mesh or small magnets are 
able to be implanted near the target tissue, allowing for a less cross-sectional approach and supposedly 
permitting a more specific attraction of the magnetic particles [97][98].  
Lately, magnetoliposomes have been studied as: MRI contrast agents to detect ischemia–reperfusion 
injuries, where a PEG coated liposome is loaded with also PEG coated SPIONS, and tested on a mouse 
liver model [99], as brain barrier penetrating doxorubicin carriers, with anti-proliferative action against 
B16 melanoma cells [100], as a doxorubicin carrier, folate targeting agent [101], and as a light/magnetic 
triggered theranostics agent [102]. 
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3. Materials and Methods 
3.1.  Chemical Materials 
Hydrazine Monohydrate (H4N2.H2O), Dextran-70 (H(C6H10O5)70OH) and Ferric Chloride (FeCl3) were 
obtained from Sigma (Sigma-Aldrich, MO, USA)  
Dimiristoyl phosphatidyl choline (DMPC), cholesteryl hemisuccinate (CHEMS) and distearoyl 
phosphatidyl ethanolamine covalently linked to to polyethylene glycol (2000) (DSPE-PEG) were 
obtained from Avanti Polar Lipids (AL, USA). 
Hydroxyethyl Piperazineethanesulfonic Acid (HEPES) was obtained from Sigma (Sigma-Aldrich, MO, 
USA). 
Dimethylthiazolyl Diphenyltetrazolium bromide (Tetrazolium dye MTT), Dimethyl sulfoxide 
(DMSO) and Cu2+(1,10-phenanthroline)3 (Cuphen) were obtained from Sigma (Sigma-Aldrich, MO, 
USA). B16F10 and MNT-1 cell lines were acquired from ATCC (ATCC LGC Standards), and 
maintained in Dulbecco’s Modified Eagle’s medium (DMEM) with high-glucose (4500 mg/l), 
supplemented with 10% fetal bovine serum and 100 IU/mL of penicillin and 100 μg/mL streptomycin. 
Phosphate-buffered saline (PBS) was obtained from Sigma (Sigma-Aldrich, MO, USA). Blood was 
taken from a donor. All other reagents were of analytical grade. 
3.2. Particle Production 
Two types of IONPs were produced: Dextran coated, and uncoated particles. 
To produce Dextran coated IONPs, 76mg of FeCl3, 100mg of Dextran-70 and 8 mL of bidistilled water, 
along with a magnetic stirrer were introduced into a reaction vial and shaken to promote dissolution. 
Then, 1 mL of H4N2.H2O was added to the solution, turning it into a dark reddish-brown hue, given a 
quick shake and then inserted into the Anton Paar Microwave Synthesis Reactor “Monowave 300”’s 
reaction chamber, set at 100ºC for 10 minutes. Uncoated particles followed the exact same procedure, 
but no Dextran-70 was added to the initial solution. 
In both particle types, a black suspension was obtained, though the uncoated particles were quick to 
sediment. The uncoated particles were separated from the solvent by centrifuge, at 2200g for 8 minutes. 
Settings were chosen such as the supernatant was clear, and the sediment would be removed from the 
vial. The coated particles would not sediment, and as such they were subject to dialysis using a dialysis 
sleeve (Medicell Int. LTD.,12000-14000 MWCO), to remove any unreacted components that remained 
in suspension.  
After either the centrifugation or dialysis, the remaining product was lyophilized, and a black powder 
for the uncoated particles and a dark brown solid for the coated particles were obtained.  
The process was modified to use Dextran-70 instead of Dextran-10 since, according to [103], Dextran-
70 produced IONPs with comparable size (21nm mean volume diameter for both) and magnetic 
properties when compared to reduced Dextran-10, without needing to resort to dextran reduction, a 12h 
long process that would need to be repeated for every IONP batch produced. If successful, these changes 
would result in an even faster and facile way to produce IONPs via a microwave assisted reaction. 
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3.3. Particle Characterisation 
After producing the particles, it became important to observe their size, so the modified procedure could 
be compared with Elizabeth Osborne’s work [87]. Two methods were used to determine particle size: 
TEM and DLS, obtaining an image with the first method, and a size value with the second. The sizing 
of these IONPs will also matter as they must be incorporated into liposomes. 
3.3.1. Transmission Electron Microscopy (TEM) 
TEM, as the name implies, is a microscopy procedure where a beam of electrons is transmitted through 
a specimen, and then magnified and focused onto a device like photographic film or a sensor to obtain 
an image. The samples are ultrathin (suspensions on a grid or ~100nm sections), and higher resolution 
images are possible due to the smaller De Broglie wavelength of electrons when compared to photons. 
Samples of both Dextran-coated and uncoated particles were prepared through the two-droplet method. 
The nanoparticles were resuspended in distilled water and a drop (5–10 μl) was placed and left to sit for 
30–60 s on a grid coated with Formvar. After this time, the suspension was partially dried, and the grid 
was then washed with distilled water, any excess water removed with filter paper. Then, sodium 
phosphotungstate (PTA, 2%, w/v) was applied to the grid for 10 s, and the excess removed with filter 
paper. Finally, the grid was left to dry at room temperature for 24 h. The samples were analyzed at an 
accelerated voltage of 20 kV (“Zeiss M10”, Germany). 
3.3.2. Dynamic Light Scattering (DLS) 
Dynamic Light Scattering, Photon Correlation Spectroscopy or Quasi-Elastic Light Scattering is a 
technique that allows one to obtain the size profile of small particles in suspension, as the IONP’s and 
magnetoliposomes produced in this work. The size values come from a relationship with the particles’ 
Brownian motion, and is called hydrodynamic diameter (called this way because it describes how a 
particle diffuses in a fluid). This motion produces an image, called a speckle pattern, an interference 
pattern derived from the changes the particles’ Brownian motion imparts on the scattering. 
The hydrodynamic diameter is calculated using the Stokes-Einstein equation: 
(3.1)         𝑑(𝐻) =  
𝑘𝑇
3𝜋𝜂𝐷
 
Where k is the Boltzmann’s constant, T is the absolute temperature, η is the viscosity of the solvent and 
D is the translational diffusion coefficient. D describes how the particles diffuse in their Brownian 
motion, and is dependant not only on the size of the particle “core”, but also its surface structure and 
medium ion types and concentrations [104].  
The DLS (“Zetasizer Nano S”, Malvern Panalytical) was used to obtain the mean particle size and the 
PdI (polydispersity index) of the IONPs. PdI describes the homogeneity of nanoparticles ranging from 
0 to a monodisperse sample up to 1.0 to a polydisperse sample. Samples were analysed at the standard 
scattering angle and wavelength of 175º and 663nm respectively, and 3 measurements with an automatic 
number of runs were taken. The samples were diluted in such a way as to get around 200 kcts on the 
equipment, since this way one can be certain that the sample is transparent enough that the solution or 
suspension will not be coloured, thus not interfering with the scattered light measurement, and that there 
is still enough sample to get an accurate evaluation. 
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3.4. Magnetoliposome Production 
Liposomes were composed of a combination of DMPC:CHEMS:DSPE-PEG at a molar ratio (57:38:5), 
and prepared by the dehydration-rehydration method [22]. 
Firstly, the lipid components were weighted and introduced into a round bottomed flask and solubilized 
with chloroform. The solvent was then evaporated in a rotary evaporator, until a thin film is formed onto 
the bottom of the flask. Hydration of the film followed, using a water suspension of coated IONPs, and 
the resulting suspension was transferred into a vial. Any liposomes still in the flask were collected via 
washing with 1 mL of deionized water (Milli-Q system; “Elix 3 Millipore”, Tokio).  
In the case of the Cuphen-loaded liposomes, a solution of this compound was also added after the solvent 
evaporation and formation of a thin lipid film [19][22]. 
The suspension is frozen and then lyophilised overnight. Controlled rehydration occurred at 30ºC, and 
involved two steps: firstly, HEPES buffer pH 7.4 (10mM HEPES, 145mM NaCl) was added in an 
amount equivalent to 20% of the original liposomal suspension volume. After a 30-minute wait, the 
remaining 80% of the buffer were added, vortexed and set to rest for another 30 minutes.  
Before extrusion, an aliquot of the suspension was taken for further analysis, and the remaining volume 
was prepared for extrusion. For that, the suspension was placed into a 10 mL vial, but not further diluted. 
The extruder (Lipex, Biomembranes Inc., Vancouver Canada) was washed with HEPES buffer, and the 
process began: the formulation was filtered under nitrogen pressure (10-500 lb/in2), through several 
polycarbonate membranes of progressively smaller pore sizes, to reduce and homogenize the liposome 
mean size. Finally, the liposomes were submitted to a gel filtration (PD-10 column filled with Sephadex), 
to remove any non-incorporated IONPs or Cuphen. The resulting suspension was ready for follow-up 
testing. 
An extensive explanation of how liposomes are prepared through the dehydration-rehydration method 
is present in Appendix I. 
3.5. Magnetoliposome Characterisation 
To characterize the magnetoliposomes, three aspects were considered: IONP incorporation, final 
liposome mean size, and physical targeting capabilities. To assess these characteristics, four separate 
procedures were conducted: a centrifuge test, a DLS assay, a lipid quantification assay and an in-vitro 
magnetism test. How each one was conducted and how they fit in the characterisation effort will now 
be described. 
3.5.1. Centrifuge Test 
IONPs incorporation in liposomes was verified via a centrifuge test. The liposomes used in this work 
do not precipitate in a benchtop centrifuge, requiring a long ultracentrifugation cycle (250,000 × g, 120 
minutes) since they present  mean size below 200 nm [19]. It is expected that the incorporation of IONPs 
in liposomes, will allow their precipitation using a benchtop centrifuge.  
To conduct this test, an Eppendorf was filled with the suspension, and centrifuged in a benchtop 
centrifuge (“Sigma 202 MK”), at 15,000 × g for 30 minutes. A second sample was taken to the 
ultracentrifuge (“Beckman LM-80”), at 42,000 × g for 20 minutes, a short centrifugation cycle that 
allowed the comparison of both experimental conditions. 
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3.5.2. Dynamic Light Scattering (DLS) 
In this step, DLS was used to measure the mean size and PdI of the magnetoliposomes. Running 
configurations were the same as IONP measurements, with standard scattering angle and wavelength of 
175º and 663nm respectively, and 3 measurements per sample with an automatic number of runs each. 
Sample dilution followed the same precept, to get the target 200kcts. 
3.5.3. Lipid Quantification 
Liposomes were characterized in terms of lipid concentration using a colorimetric method described by 
Rouser and co-workers. In this method, inorganic phosphate is converted to phosphomolybdic acid, 
which is then quantitatively converted to a blue colour due to the reduction of ascorbic acid via heating 
[105]. Briefly, samples in triplicate containing a phosphate amount between 20 to 80 nmoL (sample 
volume, less than 100 µL) were pipetted into 15 mL glass tubes. In parallel, a calibration curve was 
constructed using a 0.5 mM sodium phosphate solution. In triplicate, phosphate amounts of 20, 30, 40, 
50 60 and 80 nmoL were pipetted into glass tubes. Firstly, samples and calibration tubes are heated at 
180ºC until dryness. Then, 0.3 mL of perchloric acid was added to all tubes, the tubes were capped with 
a marble and left for 45 minutes on the hot plate. This step converts the organic lipid phosphate into 
inorganic phosphate. While the 45 minutes were ongoing, a bath was prepared, with a set temperature 
of 100ºC. Before taking the tubes to the bath, they were left to cool at room temperature and then 1 mL 
of water, 0.4 mL of ammonium hexa-molibdate and 0.4 mL of ascorbic acid were added. Every tube 
was shaken via vortex (“Vortex Genie 2”, Scientific Industries), and then set in the bath for 5 minutes. 
Finally, the tubes were again left to cool at room temperature before absorbance levels were read at 797 
nm against a blank sample in a UV-Vis spectrophotometer (“Shimadzu UV 160A”, Shimadzu Co.). 
Samples were taken after magnetoliposome rehydration, after magnetoliposome extrusion and after 
ultracentrifugation (247,130 x g, 25 minutes), sampling both the pellet and supernatant. All analysed 
samples were diluted so the respective absorbance values would fit the calibration curve. 
Curve data was fitted via linear regression, and absorbance values and sample dilutions were considered 
to calculate the phosphate lipid concentration, a value that could then give the total lipid concentration 
present in the samples. These concentrations were calculated via the following equations: 
(3.2)     𝑷𝒉𝒐𝒔/𝒕𝒖𝒃𝒆 =  
𝐴𝑏𝑠−𝑏
𝑚
 
Phos/tube refers to the amount of phosphate lipid inside the sample (in µmol), Abs refers to the 
absorbance value read by the equipment, m and b refer to the appropriate values of the linear regression 
(y=mx+b). 
(3.3)          
𝑷𝒉𝒐𝒔
𝒎𝒍
= (
𝑷𝒉𝒐𝒔
𝒕𝒖𝒃𝒆
) ∗ 𝑫𝒊𝒍𝒖𝒕𝒊𝒐𝒏 ∗
𝟏𝟎𝟎𝟎
𝑺𝒂𝒎𝒑𝒍𝒆
 
Phos/mL is the amount of phosphated lipid (in µmol) per mL of the produced liposomes, Dilution is the 
dilution factor of the sample, and Sample is the sample volume (in µL) 
(3.4)     𝑳𝒊𝒑𝒊𝒅 = (
𝑷𝒉𝒐𝒔
𝒎𝒍
) ∗
𝟏𝟎𝟎
𝟔𝟐
 
Lipid means the total of lipid (phosphate and non-phosphate, in µmol/mL), and 100/62 is a corrective 
factor: the method used only accounts for phospholipid quantification that corresponds to 62 mol% of 
the total lipid. 
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3.5.4. Cuphen Quantification 
To quantify how much Cuphen was incorporated in the magnetosomes, a spectrophotometric assay was 
used (“Shimadzu UV 160A”, Shimadzu Co.), at 270 nm. A calibration curve was built with Cuphen 
concentrations ranging from 2.5 μM to 25 μM, obtained by serial dilution of a stock solution of Cuphen 
at 200 nmoL/mL in Ethanol 100 %. Liposomes were destroyed by using the same organic solvent. 
Appropriate volumes were pipetted into eppendorfs, in triplicate. For the calibration curve 12.5 / 25 / 50 
/ 75 / 100 / 125 µL of the Cuphen stock solution (200 nmol/mL) were used. The sample volume for 
Cuphen liposomes was chosen in order to achieve absorbance values fitting the calibration curve. Next, 
Ethanol 100% was added to each, completing the volume to 1 mL. All samples were vortexed and the 
absorbances were recorded in a UV 160 Spectrophotometer (Shimadzu) against a blank sample of 
Ethanol 100%, using quartz cuvettes. Cuphen incorporation efficiency is given by the following 
expression: 
(3.5)     𝑰. 𝑬. (%) =  
(
𝑪𝒖𝒑𝒉𝒆𝒏
𝑳𝒊𝒑𝒊𝒅
)𝒇
(
𝑪𝒖𝒑𝒉𝒆𝒏
𝑳𝒊𝒑𝒊𝒅
)𝒊
∗ 𝟏𝟎𝟎  
(Cuphen/Lipid)i corresponds to the Cuphen-Lipid ratio after re-hydration and before extrusion, 
(Cuphen/Lipid)f corresponds to the Cuphen-Lipid ratio  after extrusion, gel filtration and 
ultracentrifugation, I.E. (%) is the incorporation efficiency, in percentage. 
3.6. Biocompatibility Evaluation 
It is of the utmost importance that the biocompatibility of the nanoparticles is guaranteed, since they are 
going to be parenterally administered. Even though they are incorporated in liposomes, once they release 
their contents into the target cells, the IONPs will be free, and then biocompatibility becomes an issue. 
To understand whether these nanoparticles would not interfere with cells viability or blood cells, MTT 
and haemolysis assays were conducted. 
3.6.1. MTT assay 
The MTT assay is a colorimetric method to assess cell viability and proliferation. The yellow tetrazolium 
MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) is reduced by metabolically active 
cells, in part by the action of dehydrogenase enzymes, to generate reducing equivalents such as NADH 
and NADPH. The resulting intracellular insoluble purple formazan can be solubilized with the aid of an 
organic solvent, such as DMSO and quantified by spectrophotometric means, the crystals having an 
absorbance peak at 570 nm.  
Two MTT assays were conducted simultaneously, aiming to evaluate the biocompatibility of coated 
IONPs and the interaction (if any) between the chemotherapeutic agent (Cuphen) and the coated IONPs.  
B16F10 cells at a concentration of 5 × 104 cells/mL were placed in 96-well plates (200 µl/well) for 24 
h, in standard culture conditions (37◦C, under a 5%CO2 atmosphere). Afterwards, culture medium was 
removed, and adherent cells were treated with Cuphen in free form, IONPs in free form, and the 
combination of both (200 µl/well). 
Negative control ([ ] = 0 µM) was the cell line in the presence of culture medium. After incubation for 
24 hours, the culture medium was removed from all wells (controls first, then from higher to lower 
concentration), and washed with 200 µl of PBS twice. Then, 50 µL of MTT reagent (0.5 mg/mL in 
incomplete medium) was added, followed by an incubation period of 3-4h. 100 µl of DMSO was added 
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to each well and “up and down” was performed with the pipette tip to dissolve the crystals. Absorbance 
was measured at 570 nm in a microplate reader (“Model 680”, Bio-Rad, Hercules, CA).  
The cytotoxic effect was evaluated by determining the percentage of viable/dead cells. Based on these 
values, the IC50 (concentration that reduces 50% of cellular viability) was calculated, according to an 
equation proposed by Hill and co-workers [106]. In order to determinate the IC50, two concentrations, 
X1 and X2, and the respective cell densities, Y1 and Y2, that correspond to higher or lesser than half 
cell density in negative control (Y0), were selected, according to the following equation:  
(3.5)    log 𝐼𝐶50 =  log 𝑋1 + [
𝑌1−
𝑌0
2
𝑌1−𝑌2
] ∗ (log 𝑋2 − log 𝑋1) 
Where Y0/2= half-cell density of the negative control; Y1= cell density above Y0/2; X1= concentration 
corresponding to Y1; Y2= cell density below Y0/2; X2= concentration corresponding to Y2. The IC50 
was determined by linear interpolation between X1 and X2. 
3.6.2. Haemolysis assay 
The in-vitro haemolysis assay, evaluates haemoglobin release in plasma (as an indicator of red blood 
cells lysis) following exposure to a test agent [19][107]. This procedure enables to evaluate if IONPs 
are safe for i.v. administration. 
The first step was the collection of 25 mL of human peripheral blood, EDTA-preserved. Serum was 
removed by centrifugation at 1000 g for 10 minutes, and erythrocyte suspension was subsequently 
washed with PBS at 1000 g for 10 minutes. This step was repeated three times, discarding the 
supernatant each time. 
Next, in a 96-well plate (non-sterile, round bottomed), serial dilutions of IONPs in PBS were made after 
adding 100 µl PBS in non-control wells, controls being for 100% haemolysis (200 µl water) and 0% 
haemolysis (200 µl PBS). One hundred µl of erythrocytes were then added to all wells and incubated 
for 1 hour at 37ºC. The process was repeated for the magnetosome suspension. 
After incubation, the plate was centrifuged at 1000 x g for 10 minutes, and the supernatant was 
transferred in a new 96-well plate (round bottomed). Absorbance was read at 570 nm, with a reference 
filter at 630 nm through a microplate reader Model 680 (Bio-Rad, Hercules, CA), and haemolytic 
activity was calculated. 
  
19 
 
3.7. In-Vitro Magnetism Test 
This test was designed to evaluate the IONPs ability to lead and capture the liposomes in a target area 
following their exposition to a magnetic field. 
NdFeB Magnets were bought from José Teixeira da Rocha, Unipessoal (N38, single: 40*10*4mm, 
280,2mT, stacked: 40*10*20mm, 560.9mT). 6-well cell culture plates were obtained from Greiner 
(“Cellstar”, Greiner Bio-One International GmbH). 
One of the wells from the 6-well plate was filled with a magnetosome suspension and set to rest over a 
styrofoam surface to which the stacked magnets were affixed. The surface was set on a plate jack (“Swiss 
Boy 115”, Rudolf Grauer AG), and the 6-well plate was held by a beaker clamp. This setup allowed to 
separate the magnet from the plate without disturbing the suspension, and as such reduce the local 
magnetic field enough that a full sample could be taken. Leaving the magnet in proximity to the 6-well 
plate could otherwise trap part of the sample to the bottom of the plate, inducing undesired error. 
Samples were taken at 1, 2, 4 and 19 hours, and both the lipid and Cuphen contents were determined. 
Lipid and Cuphen quantifications were done as above described. 
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4. Results and Discussion 
4.1. Particle Characterisation 
According to the work published by Osborne [87], TEM imaging of Dextran coated IONPs should show 
the distribution, shape and rough size of the iron cores, since Dextran would be transparent in TEM. It 
was also expected that the coated particles would present a smaller core and lower aggregation when 
compared to their uncoated counterparts. Aggregation is expected in nanoparticles, since the 
nanoparticles’ high surface area to volume ratio means they are both especially vulnerable to Van der 
Waals forces [108]. Furthermore, other effects depending on the suspension medium, like charge 
shielding effects in saline buffers, or protein adsorption in biological medium may contribute to 
aggregation [109].  
 
Observing Figure 4.1, the differences between coated and uncoated particles are as expected: uncoated 
nanoparticles present more aggregation and a larger iron core [87]. Unfortunately, there wasn’t enough 
image resolution to observe the core morphology. The main goal of these images to confirm that coating 
the IONPs would result in more disperse, smaller iron cores. The exact size of these cores is obscured 
by both the resolution of the image and particle aggregation. That said, measuring the hydrodynamic 
size of the whole particle was more important than investigating the iron core morphology. This was 
because these particles were meant to be loaded into liposomes, and their size in suspension would 
largely determine the properties of the carrier. 
Table 4.1: DLS sizing of Dex-70 coated IONPs, in HEPES buffer. Values expressed as average ± SD 
Batch Size (nm) PdI 
Coated IONPs 1
st
 batch 105±2 0.238±0.009 
Coated IONPs 2
nd
 batch 170±26 0.356±0.107 
Table 4.1 shows the DLS measurements of the first two batches of IONPs. They were produced in 
succession, for the first batch was meant as a test of the particle production process and was used up in 
preliminary biocompatibility tests. There is a stark difference between the hydrodynamic sizes of the 
first and second batches, possibly since these were produced in different microwave reaction chambers, 
although both chambers were the exact same brand and model. The first chamber used was sent for 
repairs and was as such out of order before any subsequent batches could be produced, and though the 
experimental setup and heating conditions of the chambers were identical, the fact is that they produced 
different sized IONPs.  
500nm 500nm 
Figure 4.1: TEM images of IONPs. Left: Dex-70 coated IONPs (1st Batch). Right: Uncoated IONPs. Scale: 2.5 cm 
= 500 nm. 
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4.2. Precipitation Test 
4.2.1. Centrifuge Test 
As mentioned in Section 3, the liposome formulation used is typically too light to precipitate in a 
benchtop centrifuge, and requires a long ultracentrifugation cycle to precipitate [19]. In the other hand, 
coated IONPs could be easily precipitated with a short centrifugation cycle in a benchtop centrifuge. 
Therefore, we could indirectly observe nanoparticle incorporation into the liposomes by measuring the 
amount of liposomes precipitated after a benchtop centrifuge cycle. 
Table 4.2: DLS sizing and lipid contents of Cuphen magnetosomes at different stages of preparation. Size values 
expressed as average ± SD. 
DMPC:CHEMS:DSPE-PEG  
(57:38:5) 
Ø (nm) PdI ± SD Lipid  
(µmol/mL) 
Initial 2384±392 1 ± 0.00 18.3 
After extrusion 162±7 0.08 ± 0.01 16.0 
After gel filtration 163±2 0.06 ± 0.02 9.9 
Table 4.2 shows size and lipid measurements taken both at different stages of production and after the 
centrifugation tests. Before extrusion, the liposomes are large and polydisperse, but extrusion greatly 
reduced both average size and PdI, at the cost of some lipid loss. Passing the magnetosomes through the 
PD-10 resulted in a lower lipid concentration, but mostly due to dilution of the suspension: until the 
desired fraction passes through the column, buffer must be repeatedly added. The suspension obtained 
after column was then used for the centrifuge tests, results in Table 4.3. 
Table 4.3:  DLS sizing and lipid contents of Cuphen magnetosomes before and after centrifugation tests. Size values 
expressed as average ± SD. 
DMPC:CHEMS:DSPE-PEG  
(57:38:5) 
Ø (nm) PdI ± SD Lipid  
(µmol/mL) 
Before centrifugation 163±2 0.06 ± 0.02 9.9 
(100%) 
Centrifugation  
15,000 × g, 30 min 
Pellet 176±2 0.06 ± 0.02 5.8  
(59%) 
UltraCentrifugation 
42,000 × g, 20 min 
Pellet 175±1 0.08 ± 0.01 5.2 
(52%) 
The centrifugation and ultracentrifugation tests were performed to confirm that IONPs were 
incorporated in liposomes. As described in methods, lower gs and time were applied to precipitate 
liposomes when compared to those used in the work published in Nave et al [19] and Pinho et al [22]. 
Comparing the results before and after the centrifugation tests, we can see both conditions led to the 
precipitation of larger liposomes, about the same size of the average IONP size (the batch used was the 
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2nd, with an average size of 170±26 nm). This suggests that IONPs were associated to liposomes and 
were responsible for liposomes precipitation.  
Centrifuging Cuphen loaded liposomes did not quite produce a pellet. Instead of that, rather two “phases” 
were formed, the separation between them was so faint that a clear image of it was not possible to be 
taken at the time. This confirms that IONPs loaded liposomes will precipitate and form a pellet, whereas 
unloaded, or only Cuphen liposomes will not form a pellet, as illustrated in Figure 4.2. 
4.2.2. Nanoparticle Influence in Liposome Production 
In order to evaluate the influence of IONPs, Cuphen liposomes were prepared in the presence or absence 
of IONPs and the respective incorporation parameters compared. Table 4.4 summarises the findings: 
Table 4.4: Physicochemical properties of Cuphen liposomes in the presence or absence of IONPs. Values expressed as 
average ± SD. 
DMPC:CHEMS:DSP
E-PEG 
 (57:38:5) 
(Cuphen/Lipid)f 
(nmol/µmol) 
I.E. (%) Ø (nm) 
(PdI) 
Ø (nm) after centrifugation 
(% of liposomes in pellet) 
Liposomes A 
With IONPs 22 ± 1 59 ± 1 162 
(<0.1) 
176 
(59%) 
Without IONPs 26 ± 1 100 ± 2 127 
(<0.1) 
130 
(47%) 
Liposomes B 
With IONPs  25 ± 1 66 ± 1 277 
(<0.1) 
282 
(80%) 
Without IONPs 35 ± 1 88 ± 3 236 
(<0.2) 
249 
(69%) 
Figure 4.2: Left: Cuphen+IONPs loaded liposomes (left) Vs water (right), after centrifugation. 
Right: Cuphen loaded liposomes (left) Vs water (right), after centrifugation. 
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The Liposome B batch was made after observing that the IONPs had a similar average mean diameter 
to the Liposome A batch. Liposome A batch magnetosomes were bigger than liposomes loaded with 
only Cuphen, had a lower incorporation efficiency of the drug and only a 60% yield. A batch with larger 
magnetosomes would hopefully allow for higher performance in incorporation and magnetosome 
production: the larger liposomes were made to be around the 200 nm range, therefore bigger than the 
average 2nd Batch IONP size (~170 nm). 
As expected, having a better fit for the average IONP left more room in the lumen for Cuphen to be 
incorporated (increased from 59% to 66%), but more importantly, increased the effective yield of 
magnetosomes (from 59% to 80%) in terms of lipid content. It should be noted that the pellets referred 
in the liposomes without IONPs have the same characteristics as those presented in Figure 4.2, where 
rather than a pellet, a sort of subtly separated “phase” formed.  
With magnetosomes produced, testing proceeded towards evaluation of their in vitro magnetic response. 
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4.3. Biocompatibility Evaluation 
Several MTT assays were conducted on both B16F10 and MNT-1 cell lines. The goal was both to be 
able to compare IONP toxicity to a known cytotoxic agent, i.e. the drug that was to be loaded alongside 
the IONPs into the liposomes, but also to test whether the presence of IONPs mixed with Cuphen would 
interfere with this drug’s activity.  
Table 4.5: Cell viability of B16F10 and MNT-1 after 24h incubation with IONPs. Values expressed as average ± SD. 
 
Cell viability (%) 
IONP Concentration 
(mg/mL) 
B16F10 MNT-1 
1 92 ± 9 85 ± 4 
2 93 ± 5 102 ± 2 
5 64 ± 6 80 ± 9 
7.5 47 ± 4 91 ± 6 
Table 4.5 indicates that the free, Dextran-70 coated IONPs, at the concentrations used, did not show any 
relevant loss of viability up to 2mg/mL. Cell viability was also evaluated for Cuphen exposure, and the 
results are presented in Figure 4.3. 
 
Figure 4.3: Cell viability of B16F10 and MNT-1 after 24h incubation with Cuphen. Values expressed as average ± SD. 
Through the method described in Section 3, the IC50 of Cuphen was found to be 4.8 ± 0.3 µM for B16F10 
and 4.3 ± 0.1 µM for MNT-1. The results are consistent with the determined IC50 values:  between 4 and 
5 µM. In addition, IONPs were also incubated with the two cell lines at the selected concentration in 
combination with Cuphen at increased concentrations ranging from 1 to 6 µM 
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Table 4.6: Cell viability of B16F10 and MNT-1 cells after a 24h incubation period with IONP at a concentration of 2mg/mL 
+ Cuphen at concentrations ranging from 1 to 6 µM. Values expressed as average ± SD. 
 
Cell viability (%) 
Tested Formulations B16F10 MNT-1 
IONPs + 1 µM Cuphen 109 ± 4 100 ± 2 
IONPs + 4 µM Cuphen 61 ± 7 62 ± 4 
IONPs + 5 µM Cuphen 49 ± 4 ------------ 
IONPs + 6 µM Cuphen 15 ± 1 21 ± 2 
Upon observation of the results on Table 4.6, no changes on cellular viability of Cuphen in the presence 
of IONPs at 2 mg/mL were observed in comparison to data in Figure 4.3. Overall the obtained results 
demonstrate that IONPs do not present cytotoxic properties towards melanoma cell lines and thus they 
may be co-incorporated in Cuphen liposomes.  
Haemolytic assays were also conducted both for IONPs and Cuphen magnetosomes, results for which 
are in Table 4.6 and 4.7, respectively.  
Table 4.6: Haemolytic effect of coated IONPs. Values expressed as average (%) ± SD. 
IONPs (mg/mL) Haemolysis (%) 
5.0 3.4 ± 0.1 
2.5 1.6 ± 0.3 
1.3 0.7 ± 0.2 
0.6 0.2 ± 0.1 
0.3 0.0 ± 0.1 
5 mg/mL was the highest concentration picked for the assay with IONPs and that from MTT assay led 
a cellular viability percentage of 64 and 80% after incubation with B16F10 and MNT-1, respectively 
Furthermore, performing serial dilutions starting at this concentration also allowed to test a 
concentration close to 2mg/mL. This allowed added certainty on whether the IONPs concentration 
chosen to be incorporated into the liposomes would be safe. 
The results revealed low haemolytic activity (< 4%) for the range of concentrations tested, further 
reinforcing the notion that the concentration that was deemed safe, 2mg/mL, is adequate for a 
biocompatible application. 
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Table 4.7 presents the haemolytic activity for Cuphen liposomes ranging from 3.1 to 200 µM co-
incorporating IONPs. The upper concentration limit was chosen to be 200 µM instead of the 750 µM 
used in magnetosome production since magnetosomes after gel filtration yielded approximately 200 µM 
Cuphen.  
Results revealed low haemolytic activity (< 5%), indicating that these magnetosomes are safe for 
intravenous administration. 
Table 4.7: Haemolytic effect of Cuphen magnetosomes. Values expressed as average (%) ± SD. 
Liposomes (Cuphen + IONPs) 
Cuphen (µM) Haemolysis (%) 
200.0 4.6 ± 1.1 
100.0 3.5 ± 0.5 
50.0 1.8 ± 0.1 
25.0 0.9 ± 0.2 
12.5 0.4 ± 0.2 
6.3 0.3 ± 0.3 
3.1 0.2 ± 0.2 
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4.4. In-Vitro Magnetism Tests - validation of magnetic properties of 
Cuphen magnetoliposomes 
4.4.1. Preliminary testing 
Before starting to design the in-vitro magnetism test proper, some preliminary tests were conducted: 
should neither the IONP suspension nor the concentrated magnetosomes exhibit any magnetic response, 
it would require a complete overhaul of the particle production process. Both a raw suspension of IONPs 
and loaded magnetosomes were exposed to a NdIB magnet (560.9mT), results shown in Figure 4.4. 
 
Figure 4.4: Preliminary magnetism tests. Left: Dex-70 coated IONP suspension.  
Centre: Dex-70 coated IONP suspension after brief exposure to a permanent magnet. 
Right: Magnetosome precipitate drawn to the magnet. 
As exhibited, the results were highly promising: the IONP suspension reacted instantly to the magnet’s 
presence, making the suspension clearer and resulting in a darker, concentrated area of IONPs as 
observed in the centre figure. The magnetosomes also responded: when concentrated they were drawn 
immediately to the magnet’s presence. A long-term assay was then planned to further gauge liposome 
magnetic targetability. 
The first suggestion was based on models of capillary flow [72] [110],to simulate the slower blood rates 
present in these superficial tumours. The self-regenerating flow would be driven through a pump, and 
the magnet would be placed near a target test section of tubing. The outflow would then be measured, 
to evaluate magnetosome retention. This was deemed to be unpractical considering the materials 
available in the lab and the low magnetosome volume available, therefore other, simpler options were 
carried out. 
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Figure 4.5: Preliminary in-vitro magnetism tests: small volume of magnetosome suspension, dyed with Blue Violet, over 
agar-agar. Two separate attempts after 15 mins. 
 
Figure 4.6: Left and Centre: Preliminary in-vitro magnetism tests: small volume of magnetosome suspension, dyed with 
Blue Violet, at T=0 and T=20 minutes.  
Right: Aftermath of the preliminary tests. Top right well suffered spillage during handling. 
Figures 4.5 and 4.6 show the first attempts at an in-vitro magnetism assay. Blue Violet was used as a 
dye, to facilitate observation of magnetosome migration towards the magnetic field. The first idea 
involved the use of agar-agar as a medium, as it was thought that it would allow for an easy capture of 
snapshots during testing, hopefully capturing the progressive formation of a colour gradient over time, 
as magnetosomes migrated from one end of the well towards the magnet. The small-scale assay involved 
just a drop over the agar-agar medium, with a magnet placed just outside the well. In sharp contrast to 
what was observed in the Falcon tube and the Eppendorf, no changes were visible even after 15 minutes. 
No deformation of the drop was observed and running the assay for a longer period of time simply 
resulted in permeation of suspension on agar. 
Another run, this time without any medium in the well, was attempted, with the magnet placed in the 
well and near the drop. After 20 minutes, no changes in the drop were visible. In hindsight, this was 
expected: the magnetosome suspension was not a ferrofluid, due to the low concentration and high size 
of IONPs, and as such it wasn’t reasonable to expect the drop to move in any significant way. This 
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meant that there was a need for a liquid medium in the wells, so that the magnetosomes were free to 
move inside the well, and towards the magnetic field.  
4.4.2. Validation of Magnetic Properties of Cuphen Magnetoliposomes  
Abandoning the drop in medium method, the magnetosome suspension was simply introduced to a small 
well, in a volume small enough such that the entire well was covered. This ended up being about 1.5 
mL, the volume that was adopted for all the subsequent in-vitro magnetism assays. The experimental 
assay was then set up with the materials available in the lab, to minimize sample perturbation during the 
assay and while removing the magnet’s influence. As described in Section 3, one of the wells from the 
6-well plate was filled with a magnetosome suspension and set to rest over a Styrofoam surface to which 
the stacked magnets were affixed. The surface was set on a plate, and the 6-well plate was held by a 
beaker clamp (Figure 4.7) 
Assays were conducted for 1, 2, 4 and 19 hours, and were all conducted separately for two reasons: the 
small volume inside the well reduced the number of samples that could reasonably be taken before there 
was insufficient coverage of the well’s bottom, and to minimize perturbation of the experiment upon 
sample collection. Having each assay only be sampled once meant that the suspension was under the 
magnetic field for the entire duration of each step, and there was no risk of resuspending any 
magnetosomes that had already settled near the target area between samplings. 
For all steps, samples were taken from: the main suspension before the 1.5 mL to fill the well were 
drawn, the location right over the magnet, the location opposite to the magnet, and from the remaining 
volume. Then, both lipid and Cuphen contents of these samples were quantified, and the concentration 
effect of the magnet was evaluated by comparing the Cuphen contents of the main suspension against 
Figure 4.7: Experimental setup for in-vitro magnetism tests. 
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the contents from the sample taken from the area over the magnet. Figure 4.8 plots the results of Cuphen 
concentration on the magnet area over time. 
 
Figure 4.8: Validation of the magnetic properties of Cuphen-loaded liposomes containing FeO NPs. Graphical 
representation of the Cuphen increase over time. Liposomes were exposed to a magnetic field of 560.9 miliTesla for a total 
period of 19 h. 
Over time, as the photos in Figure 4.8 reveal, the volume started becoming clearer, and a distinct dark 
line over the magnet formed, showing the accumulation of IONPs. It was also found that Cuphen would 
also increase its concentration over the magnet, causing some cautious optimism on the promise of this 
delivery mechanism. Lipid quantification was also conducted, results after 19h present in Table 4.9, 
when contrasts between the area over the magnet and the area away from the magnet are more visible. 
Table 4.9: Lipid quantification of Cuphen magnetosomes after a 19h magnetism test. .Values expressed as average (%) ± 
SD. 
Sample Lipid 
(µmol/mL) 
Initial 19.7 ± 0.3 
Magnet  19.4 ± 0.4 
Opposite to 
Magnet  
20.7 ± 0.8 
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Unlike Cuphen, there was not an increase in lipid over the magnet compared to the location opposite to 
it. This was unexpected, as one would think that the magnetic field would drag the magnetosomes whole 
towards the magnet, so lipid concentration should increase over time, alongside with Cuphen. As the 
assay proceeded, no significant change in lipid concentration was found. 
Two possibilities posited to explain this phenomenon were as follows:  
• The dark brown agglomeration that appears over the magnet over time could be due to free 
IONPs present in the suspension: after all, the average nanoparticle size in the 2nd Batch was 
close to the average magnetosome’s, so that separation by the PD-10 column would be difficult. 
Furthermore, the similarity in weights between free IONPs and magnetosomes (as seen in the 
precipitation tests), make them unreasonable to separate via centrifugation. This could be 
minimized by extruding the IONP suspension before making the magnetosomes or finding some 
way to produce smaller IONPs outright. This would not explain the increase in Cuphen 
concentration over time; 
• There could be liposome rupture, induced by the magnetic field, which then allows the IONPs 
to drag along any Cuphen present in the medium. Nardoni et al. (2018) [111] used a magnetic 
field to induce drug release on liposomes with IONPs and the drug both loaded intraluminally, 
akin to the magnetosomes used in this work. However, the field is an oscillating one instead of 
a permanent one, and not enough to rupture the liposomes. Kim et al.(2010) [112] managed to 
disrupt the membrane with magnetic disks, but they attack cancer cell membranes, and as such 
aren’t intraluminal. Again, an oscillating field is used. Podaru et al. (2014) [113] uses a pulsed 
magnetic field to create controlled magnetosome membrane disruption in intraluminally IONP 
loaded liposomes, and increase drug release. Membrane disruption that occurs before arriving 
to the magnet could explain the increase in Cuphen concentration, but no literature on disruption 
with permanent fields was found. 
At this point, the only certainty was that the IONP modified carrier did help concentrate the drug in the 
area targeted with a magnetic field. Magnetosome disruption seemed unlikely in our experimental setup: 
literature mentions oscillating or pulsed fields as methods of increasing drug release in situ, but no 
mention of actual carrier dismantling, only controlled membrane disruption to increase permeability. 
Even assuming that the magnetosomes were releasing either all of its contents, or just the drug, with 
Cuphen being dragged along with the IONPs that were inside the magnetosome in the first case, or 
dragged by free IONPs that were not removed from the suspension in the second case, there lacked an 
explanation for the mechanism behind Cuphen’s migration. 
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4.5. Modification Attempt 
4.5.1. New Batch Characterisation 
When producing the 3rd batch, experimental conditions were set to match the conditions of the 2nd 
batch’s production, and the batch was made using the exact same microwave reactor. The recipe used 
was still as described in Section 3. The modified batch, made to try and reduce average IONP size, had 
its changes based still in Paul et al.’s (2004) [103] work, and instead of using 100mg of Dex-70, 244mg 
of the polysaccharide were used. That one change was made so that the FeCl3/Dextran-70 ratio would 
more closely resemble the one they claim to be optimized. The previous batches used less Dextran-70 
because when compared to other coating agents, like PEG, Dextran-70 is more expensive, so if similar 
results were obtained, it would drive IONP production costs down. 
There was also the question of the size of the produced IONPs compared to literature, where the particles 
produced in this work appeared to be several times larger than those obtained by Osborne [87]. Some 
size increase was expected, since in Paul’s [103] work Dextran-70 does result in larger IONPs, but the 
values obtained were still comparatively big. Measurements were always conducted in HEPES since 
that would be the intraluminal medium of the magnetosome, so it made sense to understand the particle 
size in that medium. To be able to directly compare the sizes of the produced IONPs with those in 
literature, there was a need to conduct the DLS measurements in H2O. Table 4.10 presents the average 
nanoparticle sizes of both the 3rd Batch and the Modified Batch.  
Table 4.10: DLS sizing of modified IONPs and the 3rd batch, in HEPES and H2O. Values are expressed as average ± SD. 
Batch Size (nm) PdI 
Coated IONPs 3rd batch (in HEPES) 134 ± 37 0.436 ± 0.197 
Coated IONPs Modified (in HEPES) 117 ± 30 0.379 ± 0.137 
Coated IONPs 3rd batch (in H2O) 67 ± 23 0.204 ± 0.075 
Coated IONPs Modified (in H2O) 64 ± 6 0.342 ± 0.110 
The 3rd Batch, even though it was produced using the exact same procedure and equipment as the 2nd, 
ended up being smaller and more polydisperse (Table 4.1). Reproducing batches doesn’t appear possible 
with the current methodology, therefore some adjustments to the procedure are necessary. One possible 
approach would be to change the “as fast as possible” heating setting in the microwave reactor to a fixed 
time period. That would have the risk of exposing the reaction mix to sub-optimal reaction temperatures 
for longer, leading to an overall increased reaction time and larger particles [114]. Higher microwave 
power settings would be necessary to reduce the heating time to a minimum. 
DLS measurements in water revealed an approximate 50% reduction in average particle size when 
compared to measurements in HEPES, which means that the buffer could be inducing aggregation. 
Aggregation in buffer mediums can be mediated by charge shielding effects, where the ionic strength of 
the solution can reduce the electrostatic repulsion between nanoparticles [109][115]. One future 
experiment that can be performed to test this is a zeta potential measurement. Zeta potential serves as 
an approximation of the particles’ surface charge, and a change in zeta potential from water to HEPES 
buffer would suggest that there could be charge shielding of the IONPs [108]. 
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Figure 4.9: Modified batch after lyophilization (left) and 3rd batch after lyophilization (right) 
The differences between the Modified Batch and the 3rd Batch don’t end there, as Figure 4.9 illustrates, 
the Modified Batch produces a more compact and darker solid than the previous batches, that produced 
a flexible, very filamented brown solid. The solid produced by all batches was brittle. It would be 
interesting to understand how this change in Dextran concentration resulted in solids with different 
characteristics, but no literature was found on this subject.  
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4.5.2. FeO – Cu Interaction Hypothesis 
The opposite results in lipid and Cuphen presence near the magnet, as presented in Figure 4.10 and 
Table 4.9, encouraged exploring the possibility of the IONPs somehow directly interacting with the drug. 
It was hypothesised that the IONPs could be adsorbing the copper complex, so when a magnetic field 
attracted the IONPs, the drug would be moved towards the magnet area too.  
Guivar et al. (2017) [116] used functionalised IONPs to adsorb copper and lead ions present in aqueous 
medium, but didn’t use any polysaccharide coatings. Li et al. (2018) [117] functionalised Fe3O4 core 
and Au shell (Fe3O4@Au) nanoparticles with polydopamine for Cu(II) adsorption, while Banerjee 
[118] functionalised IONPs with Gum Arabic. These methods take advantage of how easy it is to guide 
and separate magnetic nanoparticles in solution, and their better kinetics for material adsorption due to 
these particles’ high surface area/volume ratio, often improved with specialised coating. These works 
suggest that, if the copper ion in Cuphen was available, this adsorption was possible. 
To test this hypothesis, in-vitro magnetism studies with two IONP batches (3rd Batch and Modified 
Batch) were conducted as previously described, except the IONP + Cuphen mix wasn’t incorporated 
into liposomes. Figures 4.10 and 4.11 show the magnetism test at 0h and 19h, respectively. 
 
Figure 4.10: In-vitro magnetism test at T=0h with free Cuphen + IONPs produced from the 3rd Batch (Left), and the 
modified batch (Right). 
 
Figure 4.11: In-vitro magnetism test at T=19h with free Cuphen + IONPs produced from the 3rd Batch (Left), and the 
modified batch (Right). 
After exposure to the magnetic field for 19h, and comparing with the images presented in Figure 4.8, 
one can see neither of the recent batches produces the same pronounced, dark band over the magnet area. 
That said, the Modified Batch appeared to perform better than the 3rd Batch, producing a clearer 
nanoparticle concentration band. Cuphen quantification was made to evaluate the drug’s migration, 
results presented in Table 4.11. 
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Table 4.11: Cuphen quantification after a 19 h magnetism test comparing the Modified and 3rd IONP batches. Data 
expressed as average ± SD. 
 
Sample 
Cuphen 
(nmol/mL) 
Modified Free IONPs 
+ Cuphen 
Initial 1341.9 ± 23.6 
Magnet 1329.4 ± 40.2 
Opposite to magnet 1101.6 ± 18.7 
3rd Batch Free IONPs 
+ Cuphen 
Initial 1146.9 ± 45.7 
Magnet 923.1 ± 14.7 
Opposite to magnet 876.6 ± 17.5 
As in previous magnetism tests, the area opposite to the magnet had a lower concentration of Cuphen. 
But unlike what was observed before, there was no increase in Cuphen concentration in the magnet area 
compared to the initial suspension’s concentration, even after 19h. The Modified batch did perform 
better than the 3rd Batch in retaining Cuphen in the magnet area, yet that performance was still inferior 
to the magnetosomes’. No other explanation was found to describe the results presented in Figure 4.10 
and Table 4.9, further investigation is needed to better understand this mechanism. 
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5. Conclusions 
Magnetically guided systems in medicine have seen uses from guidance of medical devices to MRI 
contrasts, drug delivery and theranostics. Melanoma, being an aggressive cancer with poor prognosis 
when in an advanced state, encourages development of drug delivery systems that improve treatment 
uptake and response. 
In this study, Iron Oxide Nanoparticles were produced to be co-incorporated with Cuphen into liposomes, 
to produce novel Cuphen magnetosomes. The IONPs’ production method differed from the work 
published by Osborne et al. [87], inspired by the study published by Paul et al., showing that Dextran-
70 coated IONPs had similar qualities to those coated with reduced Dextran-10, allowing for faster 
particle production by skipping the reduction process [103].  
TEM imaging of IONPs found that coated particles exhibited lower core sizes and less aggregation when 
compared to uncoated particles. DLS measurements of different IONP batches exhibited varying mean 
diameters in HEPES buffer, though consistently <200nm. DLS sizing in water showed particle mean 
diameter <70 nm, an evidence of aggregation of IONPs when in buffer, which could hinder separation 
of IONPs that were not incorporated from the magnetosome suspension. Even in water, the particles 
were larger than the ~20nm Dex-70 coated IONPs made by Paul and colleagues, indicating that 
obtaining smaller particles would require adjustments to production.  
Magnetosome production process was validated by centrifuge tests: benchtop centrifuging successfully 
precipitated >50% of the lipid in suspension into a pellet, with a Cuphen incorporation efficiency of 
59%. In terms of incorporation and yield, the 270nm magnetosomes boasted higher values than the 
170nm magnetosomes, an expected outcome as a larger magnetosome could incorporate more IONPs. 
The Cuphen magnetosomes were found to be fit for biological application: an IONP concentration that 
did not induce cell viability loss was chosen, and the free IONPs did not exhibit haemolytic activity 
(<2%). The IONPs also did not interfere with the cytotoxic activity of Cuphen, and magnetosomes had 
low haemolytic activity (<5%).  
Magnetic targetability of the Cuphen magnetosomes was observed: in-vitro testing revealed a 30% 
increase in Cuphen concentration over the magnet area after 19h, but the mechanism behind that 
concentration increase remains unknown: unexpectedly, there was no lipid concentration increase over 
the magnet area, and tests with only Cuphen and IONPs did not replicate the results observed with the 
Cuphen magnetosomes.  
There are ways in which this work can be expanded and improved upon, some ideas about possible 
alterations and future experiments will now be presented: 
• Testing different microwave reaction chamber heating time and power setting combinations to 
maximize batch reproducibility; 
• Determining the iron contents and coating efficiency of IONPs, either by using ICP-MS or a 
colorimetric assay that involves forming iron complexes, like the one developed by Hedayati et 
al.[119]; 
• Determining IONP incorporation efficiency by using either ICP-MS or a colorimetric assay, 
quantifying the iron present in magnetosomes; 
• Reducing average particle size by extrusion or centrifugation of the IONP solution prior to 
liposome incorporation, or explore other coatings that result in smaller IONPs; 
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• In-vivo testing in a syngeneic murine melanoma model, where effect of the Cuphen 
magnetosomes on tumour growth and survival rate can be evaluated and compared with Cuphen 
liposomes;  
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7. Appendix 
Appendix I – Liposome Synthesis 
Although liposome properties can change with which lipids are chosen, and in which ratios they are 
present, lipid vesicle production follows a generally universal procedure, divided in four main steps: 
lipid film formation, hydration, extrusion and washing. 
Lipid Film Formation 
The lipid vesicles were made by the film hydration method. DMPC, CHEMS and DSPE-PEG were 
dissolved in chloroform, obtaining a homogenous solution, in a round bottom flask. Said flask was then 
attached to a rotary evaporator, and the solvent was evaporated under vacuum until a thin film was 
obtained. 
Dehydration-Rehydration 
The film was hydrated with deionized water at 30ºC, and glass marbles were added to facilitate vesicle 
formation, as they gently scrapped the film off the flask’s bottom and promoted hydration. This was 
done until there was no more film visible in the bottom. The volume was then distributed on several 
vials, and the flask was then washed with more water to remove any lipid residue, which was then poured 
into the vials as well. 
These vials were then taken for freezing, and then lyophilized overnight. Having multiple vials with a 
portion of the volume facilitates this step. The resulting powder was rehydrated at 30ºC with HEPES 
buffer 7,4pH in two stages: firstly, 20% of the original liposome suspension volume was added, being 
vortexed repeatedly for 30 minutes. Secondly, the remaining 80% of the original suspension was added, 
and vortexed repeatedly for another 30 minutes. When the suspensions in the vials were observed to be 
homogenous, they were all added into a single vial for extrusion, and every vial was washed sequentially 
with the same volume of HEPES buffer, to gather any vesicles left behind during transfer to the larger 
vial. 
Extrusion 
Lipid extrusion describes the process through which the lipid suspension is filtered, by forcing it through 
a polycarbonate filter with a defined pore size, removing from the suspension vesicles too big for our 
goals. The filters used ranged from 1 to 0.1 µm (specifically 1.0, 0.8, 0.6, 0.4, 0.2 and 0.1)(“Whatman 
Nuclepore”), and the suspension would be passed up to three times through each size filter on a 10 ml 
extruder, to achieve minimum size dispersity. 
Washing and Concentration 
Using HEPES buffer, the extruded suspension was passed through a PD-10 column so the Sephadex gel 
would remove any small particles that were extruded along with the magnetosomes. Gravity was the 
driving force used to push the suspension through the column. After this washing, the magnetosomes 
were concentrated via ultracentrifugation (“Beckman LM-80”, 41171 x g, 20 min). 
